Lexicon Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference Transcript
Our next company presenter -- my name is Jason Gerberry. I'm the U.S. pharma analyst. I'm pleased to be introducing Lexicon Pharmaceuticals. Lonnel Coats, CEO, has a presentation.
So Lonnel, the floor is yours.
Thank you, Jason. Thank you very much. Today, I will be making forward-looking statements that may contain risk, all of our risks covered in our SEC filings, which I would suggest you read. I always make these presentations on behalf of the extraordinary men and women at Lexicon who toil daily to advance our medicines in the hands of patients. So let me jump right in.
So Lexicon's scientific platform now has produced 2 commercial products and a pipeline of innovative drugs, the first of which was introduced as XERMELO in 2017 here in the United States and then our collaborator, Ipsen, introduced XERMELO in its territories around the world, more specifically in Europe, and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |